AMEX:IBIO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally.


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.

Share Price & News

How has iBio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IBIO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.1%

IBIO

0.07%

US Biotechs

2.9%

US Market


1 Year Return

111.5%

IBIO

23.9%

US Biotechs

8.9%

US Market

Return vs Industry: IBIO exceeded the US Biotechs industry which returned 23.9% over the past year.

Return vs Market: IBIO exceeded the US Market which returned 8.9% over the past year.


Shareholder returns

IBIOIndustryMarket
7 Day3.1%0.07%2.9%
30 Day54.2%4.8%10.6%
90 Day-19.5%10.5%5.1%
1 Year111.5%111.5%25.1%23.9%11.4%8.9%
3 Year-56.6%-56.6%32.9%28.5%34.3%25.4%
5 Year-83.5%-83.5%-4.4%-10.0%60.7%42.7%

Price Volatility Vs. Market

How volatile is iBio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is iBio undervalued compared to its fair value and its price relative to the market?

44.67x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IBIO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IBIO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IBIO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: IBIO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IBIO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IBIO is overvalued based on its PB Ratio (44.7x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is iBio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

30.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as iBio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has iBio performed over the past 5 years?

-30.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IBIO is currently unprofitable.

Growing Profit Margin: IBIO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IBIO is unprofitable, and losses have increased over the past 5 years at a rate of -30.7% per year.

Accelerating Growth: Unable to compare IBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IBIO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: IBIO has a negative Return on Equity (-439.93%), as it is currently unprofitable.


Next Steps

Financial Health

How is iBio's financial position?


Financial Position Analysis

Short Term Liabilities: IBIO's short term assets ($10.3M) exceed its short term liabilities ($6.2M).

Long Term Liabilities: IBIO's short term assets ($10.3M) do not cover its long term liabilities ($32.1M).


Debt to Equity History and Analysis

Debt Level: IBIO's debt to equity ratio (30.2%) is considered satisfactory.

Reducing Debt: IBIO's debt to equity ratio has increased from 3.1% to 30.2% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IBIO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: IBIO has less than a year of cash runway if free cash flow continues to reduce at historical rates of 21.8% each year


Next Steps

Dividend

What is iBio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IBIO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IBIO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Tom Isett (54yo)

0.25

Tenure

US$66,872

Compensation

Mr. Thomas F. Isett lll, also known as Tom, has been a Director at iBio, Inc. since April 1, 2019 and also serves as Co-Chairman and Chief Executive Officer at iBio, Inc. since March, 2020. Mr. Isett is an ...


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Isett
Co-Chairman & CEO0.25yrUS$66.87k1.08% $2.2m
Robert Erwin
President11.83yrsUS$275.00kno data
James Mullaney
Chief Financial Officer3.25yrsUS$319.17kno data
Renato Lobo
Chief Medical Officerno datano datano data
R. Holtz
President of iBio CDMO1.42yrsno datano data
Carlos Picosse
Chief Executive Officer of IBio Brazil6.58yrsno datano data
Elizabeth Moyle
Secretaryno datano datano data

3.3yrs

Average Tenure

54yo

Average Age

Experienced Management: IBIO's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Isett
Co-Chairman & CEO0.25yrUS$66.87k1.08% $2.2m
Seymour Flug
Independent Director7.5yrsUS$51.87kno data
John McKey
Independent Director11.83yrsUS$51.87k0.041% $82.2k
Glenn Chang
Independent Director11.83yrsUS$51.87k0.0010% $2.1k
Robert Kay
Co-Chairman of the Board0.25yrUS$347.60k0.018% $35.7k
Vidadi Yusibov
Member of Scientific Advisory Board15.75yrsno datano data
James Hill
Independent Director11.83yrsUS$76.87k0.0013% $2.5k
Philip Russell
Independent Director10.25yrsUS$51.87kno data
Timothy Blackwell
Member of Clinical Advisory Board5.92yrsno datano data
Richard Silver
Member of Clinical Advisory Board5.92yrsno datano data

8.9yrs

Average Tenure

74.5yo

Average Age

Experienced Board: IBIO's board of directors are considered experienced (8.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 500.7%.


Top Shareholders

Company Information

iBio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: iBio, Inc.
  • Ticker: IBIO
  • Exchange: AMEX
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$200.028m
  • Shares outstanding: 118.36m
  • Website: https://www.ibioinc.com

Number of Employees


Location

  • iBio, Inc.
  • 600 Madison Avenue
  • Suite 1601
  • New York
  • New York
  • 10022
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IBIOAMEX (NYSE MKT LLC)YesCommon StockUSUSDAug 2008
0JVNDB (Deutsche Boerse AG)YesCommon StockDEEURAug 2008

Biography

iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company’s services cover the stages of pre-clinical development, regulatory approval, commercial product launch, and on-going commercial phase requirements. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. The company is also developing vaccine candidates for third parties. It has a license agreement with the University of Natural Resources and Life Sciences, Vienna; a strategic relationship with Beijing CC-Pharming Ltd.; and collaboration agreements with AzarGen Biotechnologies (Pty) Ltd, The Texas A&M University System, and Fraunhofer Center for Molecular Biotechnology. In addition, the company offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 04:01
End of Day Share Price2020/06/04 00:00
Earnings2020/03/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.